INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

BACKGROUND: Pediatric patients with relapsed or refractory disease represent a population with a desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to translate next generation molecular diagnostics into a biomarker driven treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: van Tilburg, Cornelis M., Witt, Ruth, Heiss, Melanie, Pajtler, Kristian W., Plass, Christoph, Poschke, Isabel, Platten, Michael, Harting, Inga, Sedlaczek, Oliver, Freitag, Angelika, Meyrath, David, Taylor, Lenka, Balasubramanian, Gnana Prakash, Jäger, Natalie, Pfaff, Elke, Jones, Barbara C., Milde, Till, Pfister, Stefan M., Jones, David T. W., Kopp-Schneider, Annette, Witt, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275428/
https://www.ncbi.nlm.nih.gov/pubmed/32503469
http://dx.doi.org/10.1186/s12885-020-07008-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275428/
https://www.ncbi.nlm.nih.gov/pubmed/32503469
http://dx.doi.org/10.1186/s12885-020-07008-8

Ejemplares similares